Evidence map›Paper›PMID 36271143›Full record

ArticleCommunications biology2022

Adaptation to host cell environment during experimental evolution of Zika virus.

Vincent Grass, Emilie Hardy, Kassian Kobert, Soheil Rastgou Talemi, Elodie Décembre, Coralie Guy, Peter V Markov, Alain Kohl, Mathilde Paris, Anja Böckmann and 5 more

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Experimental evolution for cell biology.Trends in cell biology · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Vincent GrassCIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, 69007, France.ORCID 0000-0001-7710-4789
Emilie Hardy *CIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, 69007, France.
Kassian Kobert *Laboratoire de Biométrie et Biologie Évolutive (LBBE), UMR CNRS 5558, Université Claude Bernard Lyon 1, Lyon, 69622, France.
Soheil Rastgou Talemi *Theoretical Systems Biology, German Cancer Research Center, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Heidelberg, 69120, Germany.ORCID 0000-0002-9999-2403
Elodie DécembreCIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, 69007, France.ORCID 0000-0001-6891-6320
Coralie GuyCIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, 69007, France.
Peter V MarkovLaboratoire de Biométrie et Biologie Évolutive (LBBE), UMR CNRS 5558, Université Claude Bernard Lyon 1, Lyon, 69622, France.
Alain KohlMRC-University of Glasgow Centre for Virus Research, Glasgow, G61 1QH, UK.ORCID 0000-0002-1523-9458
Mathilde ParisInstitut de Génomique Fonctionnelle de Lyon (IGFL), École Normale Supérieure de Lyon, Lyon, 69007, France.
Anja BöckmannInstitut de Biologie et Chimie des Protéines, MMSB, Labex Ecofect, UMR 5086 CNRS, Université de Lyon, Lyon, 69007, France.
Sara Muñoz-GonzálezCIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, 69007, France.ORCID 0000-0002-7846-7001
Lee SherryCIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, 69007, France.ORCID 0000-0002-4367-772X
Thomas HöferTheoretical Systems Biology, German Cancer Research Center, Deutsches Krebsforschungszentrum (DKFZ) Heidelberg, Heidelberg, 69120, Germany.ORCID 0000-0003-3560-8780
Bastien BoussauLaboratoire de Biométrie et Biologie Évolutive (LBBE), UMR CNRS 5558, Université Claude Bernard Lyon 1, Lyon, 69622, France. Bastien.Boussau@univ-lyon1.fr.ORCID 0000-0003-0776-4460
Marlène DreuxCIRI, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, Lyon, 69007, France. marlene.dreux@ens-lyon.fr.ORCID 0000-0002-6607-4796
Université Claude Bernard Lyon 1 · FRGerman Cancer Research Center · DEÉcole Normale Supérieure de Lyon · FRMRC University of Glasgow Centre for Virus Research · GB

Funding

Medical Research Council MC_UU_12014/8Medical Research Council MR/N017552/1
6 · The paper itself

Abstract

Zika virus (ZIKV) infection can cause important developmental and neurological defects in Humans. Type I/III interferon responses control ZIKV infection and pathological processes, yet the virus has evolved various mechanisms to defeat these host responses. Here, we established a pipeline to delineate at high-resolution the genetic evolution of ZIKV in a controlled host cell environment. We uncovered that serially passaged ZIKV acquired increased infectivity and simultaneously developed a resistance to TLR3-induced restriction. We built a mathematical model that suggests that the increased infectivity is due to a reduced time-lag between infection and viral replication. We found that this adaptation is cell-type specific, suggesting that different cell environments may drive viral evolution along different routes. Deep-sequencing of ZIKV populations pinpointed mutations whose increased frequencies temporally coincide with the acquisition of the adapted phenotype. We functionally validated S455L, a substitution in ZIKV envelope (E) protein, recapitulating the adapted phenotype. Its positioning on the E structure suggests a putative function in protein refolding/stability. Taken together, our results uncovered ZIKV adaptations to the cellular environment leading to accelerated replication onset coupled with resistance to TLR3-induced antiviral response. Our work provides insights into Zika virus adaptation to host cells and immune escape mechanisms.

Indexed as

Zika VirusZika Virus InfectionAntiviral AgentsHumansInterferonsToll-Like Receptor 3Antiviral AgentsInterferonsToll-Like Receptor 3

Identifiers

PMID36271143
PMCPMC9587232
OpenAlexW4307048183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.